PocketEdge
← All news

Desk note · industry · Pharmaceuticals / manufacturing

Piramal Pharma raised its revenue growth guidance for fiscal 2027 to about 20%

On 28 October 2026 Piramal Pharma Ltd lifted its FY27 revenue growth outlook toward the upper end of 19–20% after returning to quarterly profit, with contract development and manufacturing revenue up about 36% year on year to roughly ₹1,424 crore.

28 Oct 2026 · 2 min read

Key takeaways

  • •Piramal Pharma reported Q2 net profit of about ₹5.58 crore versus a loss of about ₹99.2 crore a year earlier, with revenue near ₹2,617 crore, up about 28% year on year, on 28 October 2026.
  • •Chairperson Nandini Piramal said the company raised FY27 growth guidance toward 19–20% from an earlier low-to-mid-teens range, expecting a stronger second half.
  • •Contract development and manufacturing revenue rose about 36% year on year to roughly ₹1,424 crore in the quarter.

What's going on here?

On 28 October 2026 Piramal Pharma Ltd reported September-quarter results that marked a turnaround to net profit and a sharper revenue outlook for fiscal 2027. Net profit was about ₹5.58 crore compared with a net loss of about ₹99.2 crore in the same quarter a year earlier. Revenue rose about 28% year on year to near ₹2,617 crore, while EBITDA reached about ₹348.7 crore in reporting cited on the day. The contract development and manufacturing organisation segment led growth, with revenue up about 36% year on year to roughly ₹1,424 crore from about ₹1,044 crore. Chairperson Nandini Piramal told reporters the company now expects annual revenue growth near 19–20%, up from an earlier low-to-mid-teens band, because the second half is typically stronger and order books look healthy across segments.

What does this mean?

CDMO growth shows global drug makers still outsourcing production and research steps to Indian facilities with cost and scale advantages. Raising guidance on a fixed-cost base implies incremental revenue should drop through to margins if utilisation stays high. The return to profit after a loss year earlier suggests restructuring and portfolio choices are stabilising, though pharma remains sensitive to regulatory inspections and customer concentration. For healthcare investors, the story is manufacturing demand rather than domestic prescription brands alone.

Why should I care?

If you work in pharma services or chemical inputs, stronger CDMO guidance can mean longer purchase orders for equipment and ingredients in Gujarat and Maharashtra industrial clusters. Patients rarely see CDMO results directly, but sustained Indian manufacturing scale keeps export earnings resilient when domestic consumption data mix is uneven. Investors should read segment splits, customer concentration, and capex plans on the earnings call rather than one-day share moves cited in headlines. Watch US FDA inspection outcomes, order wins from global innovators, and whether second-half seasonality repeats in FY27.

More desk notes

Disclaimer

For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.